임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 6건 · 완료/종료 4건
• Phase: PHASE1 · PHASE3 · PHASE2 · PHASE1, PHASE2
• Status: COMPLETED · AVAILABLE · ACTIVE_NOT_RECRUITING…
• 주요 endpoint: Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population. · Prostate cancer specific survival and overall survival will be compared for the ProstAtak® arm versus the placebo control arm. · PSA nadir will be compared for the ProstAtak® arm versus the placebo control arm. · Patient reported Health Related Quality of Life outcomes will be collected using the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. The change in QOL over time will be compared for the ProstAtak® arm versus the placebo control arm. · The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase (until the completion of radiation). Data on late effects will be collected after radiation completion.
• 등록 대상자(표본 합산): 약 1,484명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.